07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Ovarex anti-ideotype vaccine data

At the International Society of Oncodevelopmental Biology and Medicine conference in Montreux, Switzerland, AXO presented data from 100 stage III and IV ovarian cancer patients who had taken Ovarex since 1989. Ovarex induced humoral and...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

AltaRex, ViRexx Medical deal

Cancer and hepatitis B company VIR completed its acquisition of cancer company ALT. ALT shareholders received 0.5 VIR shares for each ALT share, valuing ALT at $28.4 million based on a VIR price of $1.08....
07:00 , Sep 20, 2004 |  BC Week In Review  |  Company News

Ziopharm Inc. management update

Ziopharm Inc. , New Haven, Conn.   Business: Cancer   Hired: Richard Bagley as president and COO, formerly president and CEO of AltaRex Corp.; Robert Gale as CSO and head of research, formerly SVP for...
07:00 , Jul 12, 2004 |  BC Week In Review  |  Company News

AltaRex Corp., Dompe International S.A. sales and marketing update

Dompe became the distributor in southern and eastern Europe for ALXFF's OvaRex oregovomab. The murine monoclonal antibody against CA125 is in Phase III testing to treat ovarian cancer. AltaRex Corp. (ALXFF; TSE:AXO), Waltham, Mass.  ...
07:00 , Aug 18, 2003 |  BC Week In Review  |  Company News

AltaRex Corp., United Therapeutics deal

The companies expanded an April deal under which UTHR received an exclusive license from AXO to develop and commercialize five antibodies to treat various cancers (see BioCentury, April 22). As expanded, UTHR gains rights to...
07:00 , Jun 9, 2003 |  BC Week In Review  |  Clinical News

OvaRex MAb: Phase II data; Phase III

In a Phase II trial in 145 patients, the median time to disease relapse for OvaRex patients was 13.3 months compared to 10.3 months for placebo, not a significant difference. Researchers said further analysis revealed...
07:00 , Jun 2, 2003 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch...
07:00 , May 19, 2003 |  BC Week In Review  |  Company News

AltaRex Corp. board of directors update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass.   Business: Cancer   Appointed: Antoine Noujaim, AXO founder   Resigned: Richard Bagley  ...
07:00 , May 19, 2003 |  BC Week In Review  |  Company News

AltaRex Corp. management update

AltaRex Corp. (TSE:AXO; ALXFF), Waltham, Mass.   Business: Cancer   Resigned: Richard Bagley as president and CEO; he will be replaced by AXO founder Antoine Noujam  ...
07:00 , May 12, 2003 |  BC Week In Review  |  Clinical News

OvaRex MAb: Phase II comparability data; Phase III

In a U.S. Phase II study in 26 patients, OvaRex derived from mouse ascites fluid showed no significant pharmacokinetic, immunologic or safety differences compared to OvaRex manufactured using a protein-free cell culture process. Twelve patients...